4//SEC Filing
Musso Alan A 4
Accession 0000950170-24-005790
CIK 0001680581other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 4:15 PM ET
Size
5.6 KB
Accession
0000950170-24-005790
Insider Transaction Report
Form 4
Musso Alan A
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-17+61,822→ 61,822 totalExercise: $4.01From: 2024-02-07Exp: 2033-08-06→ Common Stock (61,822 underlying)
Footnotes (1)
- [F1]This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024.
Documents
Issuer
Fulcrum Therapeutics, Inc.
CIK 0001680581
Entity typeother
Related Parties
1- filerCIK 0001295830
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 4:15 PM ET
- Size
- 5.6 KB